CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced financial results for the three and nine months ended September 30, 2011.
“In the third quarter, we continued to serve a growing number of new patients with PNH in our core territories of the US, Western Europe and Japan.”
Third Quarter 2011 Financial Results:
For the three months ended September 30, 2011, Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) reported total revenues of $204.0 million from net product sales of Soliris® (eculizumab), compared to $141.6 million in Q3 2010, reflecting steady addition of new patients with paroxysmal nocturnal hemoglobinuria (PNH) during the quarter.
